This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Radian Group (RDN) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Radian Group (RDN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Why Should You Hold on to Aon (AON) in Your Portfolio?
by Zacks Equity Research
Banking high on a growing bottom line, strategic schemes and a robust financial standing, Aon (AON) promises to reap good returns for investors.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
by Zacks Equity Research
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
Top Ranked Value Stocks to Buy for February 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, February 5th
Company News For Feb 4, 2019
by Zacks Equity Research
Companies in the news are: CI, HON, YUMC and CY
Cigna's (CI) Q4 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Cigna's (CI) Q4 earnings miss owing to a rise in expenses, which more than offset the increase in revenues.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for EUSA
Cigna (CI) Misses Q4 Earnings Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of -2.77% and 21.61%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
AON, CI Q4 Earnings Due on Feb 1: Here are Key Predictions
by Zacks Equity Research
Insurer's Q4 earnings will likely benefit from higher premiums and better investment income, partly offset by catastrophe loss and escalated expenses.
What's in the Cards for Skyworks (SWKS) in Q1 Earnings?
by Zacks Equity Research
Skyworks (SWKS) is benefiting from its portfolio strength, particularly in the 5G applications and IoT market.
Cigna (CI) Poised to Beat Q4 Earnings on Revenue Growth
by Zacks Equity Research
Cigna's (CI) Q4 results are likely to gain from increase in revenues and membership.
Here's Why You Should Hold Old Republic International Stock
by Zacks Equity Research
Old Republic International (ORI) is poised to grow given improving real estate market fundamentals, increasing home sales and housing price inflation.
Is a Beat Likely for Arthur J. Gallagher (AJG) Q4 Earnings?
by Zacks Equity Research
Stronger revenues and better-than-expected organic growth might aid Arthur J. Gallagher's (AJG) Q4. But rising expenses might be a drag.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cigna (CI) closed at $194.70 in the latest trading session, marking a +0.1% move from the prior day.
Multiline Insurance Stocks Outlook: Prospects Look Promising
by Zacks Equity Research
Strengthening of economy, improving rate environment, and adoption of technologies keep the momentum alive for multiline insurers.
Genworth Financial (GNW) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genworth Financial (GNW) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amazon Fear Grips Retail Pharmacy Space, Alliances Continue
by Urmimala Biswas
While Amazon is figuring out ways to expand in the multibillion dollar pharmacy industry, Walgreens and other industry players are ready to counter competition.
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Here's Why You Should Add Assurant (AIZ) to Your Portfolio
by Zacks Equity Research
Assurant (AIZ) rides on operational excellence and promises better rewards for investors.
What's in the Cards for UnitedHealth (UNH) Q4 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) Q4 performance should benefit from robust segmental revenues along with membership growth.
The Zacks Analyst Blog Highlights: Progressive, Cigna, Radian and Aon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Progressive, Cigna, Radian and Aon
4 Insurers Set for Q4 Earnings Beat on Multiple Tailwinds
by Zacks Equity Research
We zero in on four insurance stocks that are poised to exceed expectations in Q4 despite California wildfires weighing on underwriting profitability.
CNO Financial's Subsidiaries Get Ratings From A.M. Best
by Zacks Equity Research
CNO Financial's (CNO) arms receive rating actions from A.M. Best. Outlook is stable.